BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12086401)

  • 1. COX-2 and prostanoid receptors: good targets for chemoprevention.
    Kawamori T; Wakabayashi K
    J Environ Pathol Toxicol Oncol; 2002; 21(2):149-53. PubMed ID: 12086401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.
    Mutoh M; Watanabe K; Kitamura T; Shoji Y; Takahashi M; Kawamori T; Tani K; Kobayashi M; Maruyama T; Kobayashi K; Ohuchida S; Sugimoto Y; Narumiya S; Sugimura T; Wakabayashi K
    Cancer Res; 2002 Jan; 62(1):28-32. PubMed ID: 11782353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
    Kawamori T; Rao CV; Seibert K; Reddy BS
    Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
    Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
    Chun KS; Surh YJ
    Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
    Reddy BS; Patlolla JM; Simi B; Wang SH; Rao CV
    Cancer Res; 2005 Sep; 65(17):8022-7. PubMed ID: 16140976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 and iNOS, good targets for chemoprevention of colon cancer.
    Watanabe K; Kawamori T; Nakatsugi S; Wakabayashi K
    Biofactors; 2000; 12(1-4):129-33. PubMed ID: 11216473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ; Yu CH; Mineyama Y; McCracken JD; Hillebrand DJ; Hasan M
    Int J Oncol; 2003 Apr; 22(4):757-63. PubMed ID: 12632065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is cyclooxygenase-2 important in skin carcinogenesis?
    Fischer SM
    J Environ Pathol Toxicol Oncol; 2002; 21(2):183-91. PubMed ID: 12086405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
    Xu H; Izon DJ; Loftin C; Spain LM
    Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
    Reddy BS; Rao CV
    J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
    Chun KS; Kim SH; Song YS; Surh YJ
    Carcinogenesis; 2004 May; 25(5):713-22. PubMed ID: 14729583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
    Totzke G; Schulze-Osthoff K; Jänicke RU
    Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
    Kusunoki N; Yamazaki R; Kawai S
    Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
    Harris RE; Alshafie GA; Abou-Issa H; Seibert K
    Cancer Res; 2000 Apr; 60(8):2101-3. PubMed ID: 10786667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development.
    Kawamori T; Kitamura T; Watanabe K; Uchiya N; Maruyama T; Narumiya S; Sugimura T; Wakabayashi K
    Carcinogenesis; 2005 Feb; 26(2):353-7. PubMed ID: 15564292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2: a molecular target for colorectal cancer prevention.
    Brown JR; DuBois RN
    J Clin Oncol; 2005 Apr; 23(12):2840-55. PubMed ID: 15837998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
    Reddy BS
    Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.